

GLAXOSMITHKLINE PLC  
Form 6-K  
March 30, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 2011

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--



GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ U.S. patent litigation

Litigation continues between Pronova BioPharma and two other generic challengers

GlaxoSmithKline (GSK), which has the marketing rights for LOVAZA in the US and Puerto Rico, confirmed today that Pronova BioPharma Norge AS, which owns the patents for LOVAZA, has entered into an agreement with Apotex Corp. and Apotex Inc. (collectively "Apotex"), to settle their patent litigation in the United States related to LOVAZA.

The settlement grants Apotex a license to enter the US market with a generic version of LOVAZA in the first quarter of 2015, or earlier depending on certain circumstances. Other terms of the settlement are confidential.

Pronova BioPharma is currently still involved in lawsuits with Teva Pharmaceuticals USA, Inc., and Par Pharmaceutical, Inc., regarding its patents relating to LOVAZA.

In 2010, GSK reported LOVAZA turnover of £530 million (\$822 million). All GSK sales of LOVAZA were generated in the US and Puerto Rico.

V A Whyte

Company Secretary

30 March 2011

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit [www.gsk.com](http://www.gsk.com)

GlaxoSmithKline Enquiries:

UK Media enquiries:	David	(020) 8047
	Mawdsley	5502
	Claire Brough	(020) 8047
		5502
	Stephen Rea	(020) 8047
		5502
	Alexandra	(020) 8047
	Harrison	5502
	Janet Morgan	(020) 8047
		5502
	David Daley	(020) 8047
		5502

US Media enquiries: Nancy (919) 483  
Pekarek 2839  
Mary Anne (919) 483  
Rhyne 2839  
Kevin Colgan (919) 483  
2839  
Jennifer (919) 483  
Armstrong 2839

European Analyst/Investor enquiries: Sally (020) 8047  
Ferguson 5543  
Gary Davies (020) 8047  
5503  
Ziba Shamsi (020) 8047  
3289

US Analyst/ Investor enquiries: Tom Curry (215) 751  
5419  
Jeff (215) 751  
McLaughlin 4890

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 30, 2011

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc